Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags

American Journal of Health-System Pharmacy

Volumn 66, Issue 21, 2009, Pages 1929-1933

  Eiden, Céline ^a   Philibert, Laurent ^a   Bekhtari, Khedidja ^a   Poujol, Sylvain ^a   Malosse, Francoise ^a   Pinguet, Frédéric ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Antineoplastic agents; Chromatography, liquid; Color; Concentration; Containers; Contamination; Dextrose; Diluents; Hydrogen ion concentration; Injections; Oxaliplatin; Photodecomposition; Polyethylene; Polypropylene; Polyvinyl chloride; Stability; Storage; Temperature

Indexed keywords

GLUCOSE; OXALIPLATIN; POLYETHYLENE; POLYPROPYLENE; POLYVINYLCHLORIDE;

ARTICLE; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; CONTAINER; CONTROLLED STUDY; DILUTION; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG INFUSION; DRUG SOLUTION; DRUG STABILITY; DRUG STORAGE; FLUORESCENT LIGHTING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT EXPOSURE; PH; PRIORITY JOURNAL; STORAGE TEMPERATURE;

EID: 70449625126     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090039     Document Type: Article

References (12)

1. Goldberg RM, Sargent DJ, Morton RF et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006; 24:3347-3353
2. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350:2343-2351 (Pubitemid 38702845)
3. Gamelin E, Gamelin L, Bossi L et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002; 29:21-33. (Pubitemid 35191038)
4. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003; 30:5-13.
5. Jerremalm E, Hedeland M, Wallin I et al. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004; 21:891-894 (Pubitemid 39011316)
6. Curis E, Provost K, Bouvet D et al. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Radiat. 2001; 8:716-718 (Pubitemid 33661514)
7. Bouvet D, Michalowicz A, Crauste-Manciet S et al. EXAFS characterization of oxaliplatin anticancer drug and its deg-radation in chloride media. J Synchrotron Radiat. 2006; 13:477-483 (Pubitemid 44630235)
8. Favier B, Spath HM, Anhoury P et al. The time-saving and economic advantages of using oxaliplatin concentrated solution for infusion versus oxaliplatin lyophilised powder for infusion. www.eahp.eu/content/download/25318/ 165304/file/PRI.pdf (accessed 2009 Jul 27).
9. Food and Drug Administration. Eloxatin (oxaliplatin for injection) package insert. www.fda.gov/cder/foi/label/2004/021492s0041b1.pdf (accessed 2008 Jul 17).
10. André P, Cisternino S, Roy AL et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health Syst Pharm. 2007; 64:1950-1954 (Pubitemid 47462911)
11. Junker A, Roy S, Desroches MC et al. Stability of oxaliplatin solution. Ann Pharmacother. 2009; 43: 390-391
12. Food and Drug Administration. Guidance for industry (2001). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm072322.pdf (accessed 2009 Aug 31).